Intercept's liver disease drug proves highly effective in study
April 12, 2014 at 01:00 AM EDT
April 12 (Reuters) - A drug being developed by Intercept Pharmaceuticals Inc led to significant improvement in signs of a rare liver disease that primarily affects middle-aged women, likely reducing the risk of need for liver transplant and of death, according to results of a late-stage clinical trial presented on Saturday.